摘要
【摘要】 目的 研究分析前列地尔联合辛伐他汀治疗慢性阻塞性肺疾病（ COPD）合并肺源性心脏病的（肺心病）近期疗效。方法 此次研究的对象是选择 60例 COPD同时合并肺心病急性加重期患者，将其临床资料进行回顾性分析，并按入院先后顺序分为对照组、前列地尔治疗组和联合治疗组， 每组 20例。比较三组治疗前后氧分压（ PO2）及二氧化碳分压（ PCO2）等动脉血气分析结果、肺动脉收缩压变化及运动耐量变化情况。结果 三组治疗均有效， 治疗前后比较差异有统计学意义（ P<0.05）， 治疗后患者的缺氧及二氧化碳潴留改善程度、肺动脉收缩压降低幅度及运动耐量增加程度的比较中， 前列地尔治疗组优于对照组（ P<0.01）， 联合治疗组优于前列地尔组（ P<0.05）。结论 前列地尔联合辛伐他汀治疗 COPD合并肺心病近期疗效显著， 值得推广。
【关键词】 前列地尔；辛伐他汀；慢性阻塞性肺疾病；慢性肺源性心脏病
[Abstract] Objective To study the short-term effect of alprostadil combined with simvastatin in the treatment of chronic obstructive pulmonary disease (COPD) with pulmonary heart disease (cor pulmonale). Methods 60 patients with COPD and acute exacerbation of cor pulmonale were selected in this study. The clinical data were analyzed retrospectively. The patients were divided into control group, alprostadil group and combined treatment group according to the order of admission, 20 cases in each group. The arterial blood gas analysis results of PO2 and PCO2, the changes of pulmonary systolic pressure and exercise tolerance were compared before and after treatment. Results the three groups were effective, and the difference was statistically significant (P<0.05). After treatment, the improvement of the degree of hypoxia and carbon dioxide retention, the reduction of pulmonary artery systolic pressure and the increase of exercise tolerance * were better than those of the control group (P<0.01). The combined treatment group was superior to the alprostadil group (P<0.05). Conclusion alprostadil combined with simvastatin has a significant short-term effect on COPD with cor pulmonale, which is worth popularizing.
出版日期
2020年09月14日（中国期刊网平台首次上网日期，不代表论文的发表时间）
